logo-loader
viewPuma Biotechnology Inc

Puma Biotechnology shares surge on breast cancer drug review news

The benefits of the drug reportedly outweigh the risks, according to briefing documents.

rsz_shutterstock_161304095.jpg
The candidate is a treatment for early stage breast cancer

Puma Biotechnology Inc (NASDAQ:PBYI) raced up almost 40% in early deals in New York on positive FDA developments.

The powerful US Food and Drug Administration posted briefing documents ahead of its review this week of the company's PB272 (neratinib) for the extended treatment of positive early stage breast cancer.

The benefits of the drug, which addresses an unmet need after the standard of care second-line cancer therapy, reportedly outweigh its risks, according to briefing documents.

The FDA's oncologic drugs advisory committee is scheduled to meet about the drug on Wednesday, and such recommendations are considered by the FDA when deciding whether or not to to approve a drug.

Shares added over 39% to stand at $52.65.

Quick facts: Puma Biotechnology Inc

Price: 10.815 USD

NASDAQ:PBYI
Market: NASDAQ
Market Cap: $425.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Phunware beats out major company to become app of choice for...

Phunware (NASDAQ: PHUN) CEO Alan Knitowski joined Steve Darling from Proactive Vancouver with news the company has beat out giant Salesforce to become of the app of choice for the re-election campaign of Donald J Trump and Mike Pence. Knitowski talks about winning that contract and what their...

10 hours, 7 minutes ago

2 min read